Comparative effectiveness of H7N9 vaccines in healthy individuals

Co-circulation of multiple genotypes of influenza A (H7N9) viruses in eastern China, 2016-2017

(2018) Xian Qi et al.   ARCHIVES OF VIROLOGY

WHO is “cautiously optimistic” about Ebola ring vaccination programme in DRC

(2018) Jacqui Wise   BMJ-British Medical Journal

WHO is “cautiously optimistic” about Ebola ring vaccination programme in DRC

(2018) Jacqui Wise   BMJ-British Medical Journal

Genesis and Spread of Newly Emerged Highly Pathogenic H7N9 Avian Viruses in Mainland China

(2017) Lei Yang et al.   JOURNAL OF VIROLOGY

Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial

(2017) Anuradha Madan et al.   VACCINE

Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial

(2017) Un-In Wu et al.   VACCINE

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

(2017) Adam D. DeZure et al.   npj Vaccines

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults

(2016) Anuradha Madan et al.   JOURNAL OF INFECTIOUS DISEASES

H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial

(2016) Larisa Rudenko et al.   LANCET INFECTIOUS DISEASES

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response

(2015) Lisa A. Jackson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)

(2015) Mahdee Sobhanie et al.   JOURNAL OF INFECTIOUS DISEASES

ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans

(2015) Ka Yan Chung et al.   VACCINE

A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03

(2015) Takeshi Naruse et al.   VACCINE

Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant

(2014) Mark J. Mulligan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Characterization of H7 Influenza A Virus in Wild and Domestic Birds in Korea

(2014) Hyun-Mi Kang et al.   PLoS One

A Cell Culture-Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults

(2014) S. A. Bart et al.   Science Translational Medicine

Clinical, Virological, and Histopathological Manifestations of Fatal Human Infections by Avian Influenza A(H7N9) Virus

(2013) Liang Yu et al.   CLINICAL INFECTIOUS DISEASES

Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses

(2013) Di Liu et al.   LANCET

Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome

(2013) Yu Chen et al.   LANCET

A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine

(2013) Louis F. Fries et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus

(2013) Rongbao Gao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantitative Description of Glycan-Receptor Binding of Influenza A Virus H7 Hemagglutinin

(2013) Karunya Srinivasan et al.   PLoS One

Human H7N9 avian influenza virus infection: a review and pandemic risk assessment

(2013) Kang Yiu Lai et al.   Emerging Microbes & Infections

Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned?

(2012) V. C. C. Cheng et al.   CLINICAL MICROBIOLOGY REVIEWS

The history of MF59®adjuvant: a phoenix that arose from the ashes

(2012) Derek T O’Hagan et al.   Expert Review of Vaccines

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases

(2012) A. Baz Morelli et al.   JOURNAL OF MEDICAL MICROBIOLOGY

A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine

(2012) Robert B. Couch et al.   PLoS One

Adjuvants in influenza vaccines

(2012) Kohhei Tetsutani et al.   VACCINE

Human-like PB2 627K Influenza Virus Polymerase Activity Is Regulated by Importin-α1 and -α7

(2012) Ben Hudjetz et al.   PLoS Pathogens

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

(2011) Theodore F. Tsai et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

(2011) Samuele Calabro et al.   VACCINE

Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling

(2011) Felix Geeraedts et al.   PLoS Pathogens

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

(2010) Steven Black et al.   VACCINE

HIV gp41 Engages gC1qR on CD4+ T Cells to Induce the Expression of an NK Ligand through the PIP3/H2O2 Pathway

(2010) Hugues Fausther-Bovendo et al.   PLoS Pathogens

Neuraminidase Stalk Length and Additional Glycosylation of the Hemagglutinin Influence the Virulence of Influenza H5N1 Viruses for Mice

(2009) Y. Matsuoka et al.   JOURNAL OF VIROLOGY

A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine

(2009) Rebecca J. Cox et al.   VACCINE

Pandemic Influenza Vaccines – The Challenges

(2009) Lars Haaheim et al.   Viruses-Basel

Alum adjuvanticity: Unraveling a century old mystery

(2008) Ennio De Gregorio et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA